Predicting dosing advantages of factor VIIa variants with altered tissue factor-dependent and lipid-dependent activities

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 8, 2014, Pages 1302-1312

  Shibeko, A M ^a   Woodle, S A ^b   Mahmood, I ^b   Jain, N ^b   Ovanesov, M V ^b  

^a CENTER FOR THEORETICAL PROBLEMS OF PHYSICOCHEMICAL PHARMACOLOGY   (Russian Federation)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Factor VIIa; Hemophilia; Pharmacology; Thrombin; Thromboplastin

Indexed keywords

ENZYME PRECURSOR; LIPID; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN;

ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EX VIVO STUDY; HEMOPHILIA A; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; LOW DRUG DOSE; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; HALF LIFE TIME; PHYSIOLOGY;

FACTOR VIIA; HALF-LIFE; HUMANS; LIPIDS; RECOMBINANT PROTEINS; THROMBOPLASTIN;

EID: 84906101602     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12628     Document Type: Article

References (50)

1. Hoffman M, Monroe DM III. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001; 38: 6-9.
2. Pittman D, Weston S, Shields K, Parng C, Arkin S, Madison E, Nichols TC, Fruebis J. A novel FVIIa variant with increased potency and duration of effect compared to wildtype FVIIa. A study in a dog model of hemophilia A. Blood 2011; 118: 2252.
3. Nielsen AL, Ruf W, Holmberg HL, Buchardt J, Sorensen B, Olsen OH, Ostergaard H. Design of a potent phospholipid membrane-dependent factor VIIa variant. J Thromb Haemost 2013; 11: 237.
4. Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci USA 2001; 98: 13583-8.
5. Allen GA, Persson E, Campbell RA, Ezban M, Hedner U, Wolberg AS. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007; 27: 683-9.
6. Mahlangu JN, Coetzee MJ, Laffan M, Windyga J, Yee TT, Schroeder J, Haaning J, Siegel JE, Lemm G. Phase I randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost 2012; 10: 773-80.
7. Metzner HJ, Weimer T, Schulte S. Half-life extension by fusion to recombinant albumin. Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 2012; 223-47.
8. Hart G, Hershkovitz O, Bar-Ilan A, Seligsohn U, Fima E. Factor VIIa-CTP, a novel long-acting coagulation factor, displays a prolonged hemostatic effect and augmented pharmacokinetics and pharmacodynamics following IV and SC administration in hemophilic animal models. Blood 2012; 120: 1114.
9. Tan S, Salas J, Chen K, Kistanova E, Ashworth T, Acosta M, Johnson B, Pape B, Pierce GF, Light D, Mei B, Schellenberger V, Peters RT, Jiang H. A platelet-targeted factor VIIa.XTEN fusion protein with increased circulating half-life and improved clotting activity. J Thromb Haemost 2013; 11: 586.
10. Ljung R, Karim FA, Saxena K, Suzuki T, Arkhammar P, Rosholm A, Giangrande P. 40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics, and preliminary efficacy in hemophilia patients with inhibitors. J Thromb Haemost 2013; 11: 1260-8.
11. Sorensen BB, Kjalke M, Zopf D, Bjorn SE, Stennicke HR. Platelet-dependent activity of GlycoPEGylated rFVIIa. Blood (ASH Annual Meeting Abstracts) 2007; 110: 3140.
12. Retzios AD. The New and Improved (?) Activated Factor VII Molecules. http://adrclinresearch.com/Issues_in_Clinical_Research_links/The%20New%20Factor%20VIIas_18May2011.pdf. Accessed 18 June 2014.
13. Collins PW, Moss J, Knobe K, Groth A, Colberg T, Watson E. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost 2012; 10: 2305-12.
14. Eichinger S, Lubsczyk B, Kollars M, Traby L, Zwiauer K, Gleiss A, Quehenberger P, Kyrle PA. Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa. Eur J Clin Invest 2009; 39: 707-13.
15. Shirahata A, Fukutake K, Mimaya J, Takamatsu J, Shima M, Hanabusa H, Takedani H, Takashima Y, Matsushita T, Tawa A, Higasa S, Takata N, Sakai M, Kawakami K, Ohashi Y, Saito H. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors - phase I trial: 2nd report. Haemophilia 2013; 19: 330-7.
16. Spira J, Plyushch O, Zozulya N, Yatuv R, Dayan I, Bleicher A, Robinson M, Baru M. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII - an open label, exploratory, cross-over, phase I/II study. Haemophilia 2010; 16: 910-18.
17. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116: 5734-7.
18. Shibeko AM, Woodle SA, Lee TK, Ovanesov MV. Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood 2012; 120: 891-9.
19. Butenas S, Branda RF, van't Veer C, Cawthern KM, Mann KG. Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 2001; 86: 660-7.
20. Morfini M, Jimenez-Yuste V, Eichler H, Fischer R, Kirchmaier CM, Scharling B, Bjerre J. Pharmacokinetic properties of two different recombinant activated factor VII formulations. Haemophilia 2012; 18: 431-6.
21. Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-48.
22. Agerso H, Tranholm M. Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia. Haemophilia 2012; 18: 6-10.
23. Turecek PL, Varadi K, Keil B, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, Linari S, Schwarz HP. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003; 33: 16-22.
24. Ovanesov MV, Panteleev MA, Sinauridze EI, Kireev DA, Plyushch OP, Kopylov KG, Lopatina EG, Saenko EL, Ataullakhanov FI. Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution. Blood Coagul Fibrinolysis 2008; 19: 743-55.
25. Klintman J, Astermark J, Berntorp E. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma. Br J Haematol 2010; 151: 381-6.
26. van Veen JJ, Gatt A, Bowyer AE, Cooper PC, Kitchen S, Makris M. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents. Int J Lab Hematol 2009; 31: 189-98.
27. Nakatomi Y, Nakashima T, Gokudan S, Miyazaki H, Tsuji M, Hanada-Dateki T, Araki T, Tomokiyo K, Hamamoto T, Ogata Y. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent. Thromb Res 2010; 125: 457-63.
28. Livnat T, Martinowitz U, Zivelin A, Rima D, Kenet G. A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor. Thromb Haemost 2011; 105: 688-95.
29. Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009; 15: 904-10.
30. Chambost H, Santagostino E, Laffan M, Kavakli K. Real-world outcomes with recombinant factor VIIa treatment of acute bleeds in haemophilia patients with inhibitors: results from the international ONE registry. Haemophilia 2013; 19: 571-7.
31. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
32. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
33. -1) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres. Haemophilia 2009; 15: 760-5.
34. -1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287-94.
35. Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis. CMAJ 2011; 183: E9-19.
36. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
37. Harrison JF, Fegan C, Dasani H, Bloom AL. Clinical effect of recombinant human activated factor VII (rVIIa NOVO). Br J Haematol 1991; 77: 3 V008.
38. Macik BG, Lindley CM, Lusher J, Sawyer WT, Bloom AL, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study. Blood Coagul Fibrinolysis 1993; 4: 521-7.
39. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
40. Hedner U, Bjoern S, Bernvil SS, Tengborn L, Stigendahl L. Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors. Haemostasis 1989; 19: 335-43.
41. Butenas S, Brummel KE, Bouchard BA, Mann KG. How factor VIIa works in hemophilia. J Thromb Haemost 2003; 1: 1158-60.
42. Baudo F, Collins P, Huth-Kuhne A, Levesque H, Marco P, Nemes L, Pellegrini F, Tengborn L, Knoebl P. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120: 39-46.
43. Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in US hospitals: analysis of hospital records. Ann Intern Med 2011; 154: 516-22.
44. Auerswald G, Muntean W, Kemkes-Matthes B, Klamroth R, Krause M, Kurnik K, Oldenburg J, Pabinger-Fasching I, Schramm W, Zimmermann R, Zotz RB. [Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - recommendations from the GTH experts]. Hamostaseologie 2009; 29: 197-203.
45. Shapiro AD. Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors. Clin Adv Hematol Oncol 2008; 6: 579-86.
46. Tranholm M, Kristensen K, Kristensen AT, Pyke C, Rojkjaer R, Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003; 102: 3615-20.
47. de Paula EV, Kavakli K, Mahlangu J, Ayob Y, Lentz SR, Morfini M, Nemes L, Salek SZ, Shima M, Windyga J, Ehrenforth S, Chuansumrit A. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost 2012; 10: 81-9.
48. Feng D, Whinna H, Monroe D, Stafford DW. FVIIa as used pharmacologically is not TF dependent in hemophilia B mice. Blood 2014; 123: 1764-6.
49. Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25: 4007-20.
50. Sorensen BB, Persson E, Freskgard PO, Kjalke M, Ezban M, Williams T, Rao LV. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997; 272: 11863-8.